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CHLOROQUINE INDUCTION PAR-4 AND 
TREATMENT OF CANCER 
This application claims priority to U.S. provisional appli-
cation No. 62/169,406 filed Jun. 1, 2015, the disclosure of 
which is incorporated herein by reference in its entirety. 
FIELD OF THE INVENTION 
The present invention relates to methods for treating 
cancer in a subject by administering chloroquine to a subject 
in need thereof. The chloroquine is administered in amounts 
sufficient to induce production and/or secretion of the tumor 
suppressor prostate apoptosis response-4 ("Par-4") by nor-
mal cells, preferably in an amount sufficient to inhibit 
proliferation and/or metastasis of cancer cells, and/or reduce 
the recurrence of tumors. The chloroquine may be admin-
istered with or without a chemotherapeutic and optionally 
may be administered with curcumin and/or ibuprofen. The 
chloroquine may also optionally be administered with ion-
izing radiation. 
BACKGROUND OF THE INVENTION 
The development and progression of cancer is a multistep 
process involving accumulation of multiple genetic aberra-
tions. Most notable among such aberrations is the loss of 
apoptotic responses that normally serve as built in check-
points against the emergence of cell populations with dys-
functional traits or the acquisition of pro-survival mecha-
nisms that override the apoptotic signals. The loss of 
apoptotic mechanisms often results in abridged response to 
cancer therapy. As such, alternate or combinatorial 
approaches that kill cancer cells and induce tumor regression 
are being actively pursued by researchers and physicians. 
Especially difficult to treat are those cancers which are 
hormonally related and/or are metastatic cancers. These 
cancers include, e.g., prostate cancer, breast cancer and lung 
cancer. Melanoma is also difficult to treat and has a low 
survival rate relative to many other cancers. 
An essential feature of anticancer strategies is the selec-
tive action against cancer cells, with little or no damage 
inflicted in normal cells. Nonetheless, side effects of cancer 
therapies are often severe. They include nausea, vomiting, 
pain, poor appetite, wasting, cachexia, diarrhea, burning in 
the stomach, stress, planter warts, nerve death-neuropathy, 
radiation burns, fatigue, constipation, anemia, anxiety, 
weakened immune system, dry skin, bone marrow suppres-
sion and hair loss. As such the identification of molecules 
that can specifically target tumor cells, with minimal or no 
adverse effects to normal cells constitutes a significant area 
of cancer research. Such molecules with selective action 
against tumor cells are valuable not only for their therapeutic 
potential; but also for their potential applications as tools for 
dissection of fundamental differences between normal and 
cancer cells. Thus, treatment methods that specifically target 
certain types of hormonally linked cancers would be 
extremely useful. Additionally, treatment methods that target 
cancers located in highly vascularized tissues such as for 
example lung, kidney, liver, or blood, and methods that 
target difficult to treat cancers, such as for example mela-
noma, would also be highly beneficial. 
BRIEF DESCRIPTION OF THE INVENTION 
The tumor suppressor Par-4 (prostate apoptosis response-
4) induces apoptotic cell death specifically in cancer cells 
2 
but not in normal cells. This cancer-selective action is 
attributed to its centrally located SAC domain (EI-Guendy et 
al. (2003) "Identification of a unique core domain of Par-4 
sufficient for selective apoptosis-induction in cancer cells." 
5 Mal. Cell. Biol. 23, 5516-5525). 
The Par-4 protein has not only an intracellular function, 
but it is also secreted by both normal and cancer cells 
(Burikhanov et al. (2009). "The tumor suppressor Par-4 
activates an extrinsic pathway for apoptosis" Cell 138, 
10 377-388.). Secreted Par-4 binds to its receptor GRP78, 
which is upregulated on the surface of cancer cells, and 
induces apoptosis (Burikhanov et al. (2009); Bhattarai, T, 
and Rangnekar V M (2010) "Cancer-selective apoptotic 
effects of extracellular and intracellular Par-4" Oncogene 
15 29, 3873-3880). The basal level of Par-4 secreted by normal 
cells is inadequate to induce apoptosis of cancer cells or 
inhibit the growth of tumors (Burikhanov et al. (2009)). 
However, elevated levels of extracellular Par-4 produced by 
injecting recombinant Par-4 in mice, cause inhibition of 
20 metastatic lung tumors (Zhao et al. (2011) "Systemic Par-4 
inhibits metastatic tumor growth". Cancer Biol Ther. 12, 
152-157). 
There are several non-FDA approved small molecules, 
such as Nutlin-3a, PS-1145, and Arylquin-1 (INV13/1947) 
25 that can increase secretion of Par-4 from normal cells in 
mice and the sera from these mice induced ex vivo apoptosis 
in cancer cell cultures (Burikhanov et al. (2014) "Paracrine 
apoptotic effect of p53 mediated by tumor suppressor Par-
4 ". Cell Reports 6, 271-277; and Burikhanov et al., 
30 "Arylquin-1 targets vimentin to trigger Par-4 secretion for 
tumor cell apoptosis" Nature Chem Biol. 10, 924-926 
(2014)). 
Disclosed herein is the discovery that chloroquine induces 
Par-4 secretion via the classical secretory pathway that 
35 requires activation of p53. Mechanistically, p53 directly 
induces Rab8b, a GTPase essential for vesicle transport of 
Par-4 to the plasma membrane prior to secretion. 
In particular, described herein is the discovery that the 
anti-malarial drug, chloroquine, including in various salt 
40 forms, induces robust Par-4 production from normal human 
and mouse cells and can be used to inhibit proliferation 
and/or metastasis of cancer cells, and to inhibit recurrent 
tumor formation in subjects in need thereof. The induction 
of Par-4 by normal cells in response to chloroquine treat-
45 ment may be enhanced by administering chloroquine with 
curcumin and/or ibuprofen. Likewise, chloroquine treatment 
may be used to sensitize cancer cells to ionizing radiation. 
Described herein are methods for harnessing the ability of 
Par-4 secreted from normal cells to induce apoptosis and 
50 inhibit tumor growth of cancer cells. In the methods 
described herein, chloroquine, with or without curcumin 
and/or ibuprofen, does not require administration of a che-
motherapeutic to enhance induction of Par-4 by normal cells 
and inhibit proliferation and/or metastasis of cancer cells or 
55 to inhibit recurrent tumor formation. Thus, in an aspect of 
this invention, chloroquine is administered without a che-
motherapeutic agent. Also an aspect of this invention is a 
method for treating a subject having cancer cells that are 
p53-deficient but nonetheless unexpectedly undergo apop-
60 tosis in response to Par-4 exposure, by administering an 
effective amount of chloroquine to the subject. An effective 
amount of chloroquine is sufficient to increase Par-4 secre-
tion by normal cells to a level that induces apoptosis of the 
cancer cells, and/or inhibits proliferation of such cancer cells 
65 and/or inhibits metastasis of such cancer cells. 
Also an aspect of this invention is a method for treating 
a subject having cancer cells that are p53-deficient and are 
US 10,512,641 B2 
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resistant to apoptosis induced by Par-4 exposure. The 
method comprises increasing the amount of Par-4 receptor 
on such cells, e.g., by administering an effective amount of 
an NF-kB inhibitor, e.g., PS-1145, and administering an 
effective amount of chloroquine to the subject. An effective 5 
amount of NF-KB inhibitor is an amount sufficient to elevate 
4 
H1299 relative to the background level apoptosis produced 
by aliquots of pre-HCQ treatment serum. 
FIG. 2E demonstrates that apoptosis ofH460 cancer cells 
by post-treatment serum from RCC4 was neutralized by the 
Par-4 (P) or GRP78 (G) antibody. 
FIG. 2F demonstrates the serum from mice treated with a 
single dose of CQ but not the serum from control vehicle-
treated mice induced ex vivo apoptosis of cancer cells, and 
this activity was neutralized by the Par-4 (P) or GRP78 (G) 
the level of Par-4 receptor, thereby increasing the cancer 
cells' responsiveness to apoptosis induced by Par-4. An 
effective amount of chloroquine is an amount sufficient to 
increase Par-4 secretion by normal cells to a level that kills 
the p53-deficient cancer cells, e.g., by inducing apoptosis of 
the p53-deficient cancer cells, and/or inhibits proliferation of 
such cancer cells and/or inhibits metastasis of such cancer 
cells, in the presence of Par-4. 
10 antibody. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-B depict the induction of Par-4 secretion by 
chloroquine in various normal cell lines (FIG. lA), but not 
in prostate or lung cancer cell lines (FIG. lB). Normal cells 
lines are mouse embryonic fibroblasts (MEFs, early passage 
4 or 5), human primary prostate fibroblast cells (PrSC), 
human primary prostate epithelial cells (PrEC), human lung 
embryonic fibroblasts (HEL), human bronchial epithelial 
cells (HBEC). The human prostate cancer cell lines are 
androgen-dependent LNCaP cells, and androgen-indepen-
dent ( castration-resistant) C4-2B, DU145 and PC-3 cells and 
lung cancer cell lines are H460 and A549. 
15 
FIG. 3A depicts the apoptotic effects of CM from Par-4+/+ 
MEFs but not with Par-MEFs treated with chloroquine on 
LLCl cells and this apoptotic activity in the CM was 
inhibited by the Par-4 (P) antibody or GRP78 (G) antibody. 
FIG. 3B demonstrates that chloroquine inhibits tumor 
growth by a Par-4-dependent mechanism. 
FIG. 3C demonstrates the serum from mice treated with 
CQ but not the serum from control vehicle treated mice 
induced ex vivo apoptosis of cancer cells and this apoptotic 
20 activity in the CM was inhibited by the Par-4 (P) antibody 
or GRP78 (G) antibody. 
FIGS. 4A-4D demonstrate that chloroquine induces Par-4 
secretion by the classical secretory pathway that is depen-
dent on VACA suppression by p53 and by inhibition of 
25 NF-KB activity. 
FIG. 4A depicts response of wild type or p53-null MEFs 
treated with chloroquine or Nutlin-3a. Robust induction of 
Par-4 secretion is seen in wild type MEFs but not in p53-null 
MEFs in response to chloroquine treatment. 
FIG. 4B depicts inhibition of NF-KB activity, but not AP! 
activity, by chloroquine in normal cells but not in cancer 
cells. 
FIGS. lC-D depict chloroquine-induced systemic expres- 30 
sion of Par-4 in mice and in patients. FIG. lC is a western 
blot of serum samples of C57 /BL6 mice collected 24 hours 
after treatment with chloroquine. FIG. lD is a western blot FIG. 4C depicts chloroquine inhibition of UACA expres-
sion in MEF, but not p53 null MEFs, (left panels) and in 
35 HELs. 
of pre-operative and post-operative serum samples collected 
from renal cell carcinoma patients who received hydroxy-
chloroquine ("HCQ") (400 mg daily for 2-weeks) pre-
operatively at the University of Pittsburgh, as part of a 
clinical trial in 2010-2011. 
FIGS. 2A-F demonstrate apoptosis in cancer cell cultures 
by chloroquine-inducible Par-4 secretion in conditioned 40 
medium (CM) of normal cells. Cancer cells are p53-wild 
type lung cancer cells H460 and A549, p53-deficient lung 
cancer cells (HOP92 and H1299), and p53-deficient prostate 
cancer cells (PC-3 and DU145). Normal cells (HEL). An 
asterisk(*) indicates statistical significance (P<0.001) by the 45 
Student's t-test. A549 and DU145 cells lack cell surface 
receptors, and therefore served as an internal control for 
resistance to the apoptotic action of Par-4. 
FIG. 4D depicts inhibition of CQ-induced Par-4 expres-
sion by BFA. 
FIG. 5 depicts enhanced secretion of Par-4 in cells treated 
with both chloroquine and curcumin or ibuprofen. 
FIG. 6A depicts CQ induced inhibition of tumor nodules 
in the lungs of nude mice in the presence of control IgG or 
but not in the presence of Par-4 antibody. 
FIG. 6B demonstrates CQ does not significantly inhibit 
the growth of subcutaneous bulky tumors. 
FIG. 7A depicts CQ induced Par-4 secretion by a p53-
dependent mechanism. P53+/+ or p53-/- MEFs were 
treated with CQ (25 µM), Arylquin-1 (500 µM), Nutlin-3a 
(10 µM) or vehicle (V) for 24 hand the CM and lysates were 
examined by Western blot analysis with the indicated anti-FIG. 2A demonstrates that serum from Par-4+/+ mice but 
not Par-4_1_ mice injected with chloroquine showed robust 
Par-4 secretion relative to serum from vehicle-treated mice. 
50 bodies. 
FIG. 2B demonstrates that serum from chloroquine-
treated Par-4+/+ mice induced ex vivo apoptosis in H460 
cells, and this action of serum was neutralized by the Par-4 
(P) or GRP78 (G) antibody but not by the control (C) 
antibody. 
FIG. 2C depicts that A549 cells treated with the NF-KB-
inhibitor PS-1145, which elevates Par-4 receptor GRP78 on 
the cancer cell surface (Burikhanov et al. "Novel mechanism 
FIG. 7B depicts CQ inhibition ofUACA expression. Wild 
type MEFs and p53-/- MEFs (left panel) or HEL cells (right 
panel) were treated with CQ (25 µM) or vehicle (V) for 24 
h and the CM and lysates were examined by Western blot 
55 analysis with the indicated antibodies. 
FIG. SA depicts CQ induced p53-dependent transcription 
and upregulation of p53-responsive genes. 
FIG. SB depicts CQ induced upregulation of p53-respon-
sive genes. 
of apoptosis resistance in cancer mediated by extracellular 60 
PAR-4". Cancer Res. 73: 1011-1019, 2013. PMCID: 
FIG. SC demonstrates CQ does not elevate Par-4 RNA 
levels. 
PMC3549021 ), were sensitized to apoptosis by Par-4 
secreted in CM from MEFs in response to chloroquine 
treatment. 
FIG. 2D demonstrates that the serum from a patient who 
showed-3-fold induction of Par-4 following HCQ treatment 
induces apoptosis in cancer cells PC-3, H460, HOP92, and 
FIG. SD demonstrates CQ did not induce p53 or Rab8b, 
or VACA downregulation in cancer cells. 
FIGS. 9A-9D demonstrate that Rab8b is a novel target of 
65 p53 critical for Par-4 secretion from normal cells. FIG. 9A 
demonstrates that Rab8b-null MEF cells, but not Rab8a-null 
MEF cells, failed to show induction of Par-4 secretion by 
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CQ. FIG. 9B demonstrates that CQ induced Par-4 secretion 
in Rab8b-null MEFs transiently transfected with mouse 
Rab8b expression construct or with vector for control. FIG. 
9C demonstrates that knocking down Rab8b with siRNAs 
resulted in inhibition of Par-4 secretion in the CM, as judged 
by Western blot analysis. FIG. 9D demonstrates that Par-4 
secretion is rescued with the reintroduction of GFP-Rab8b 
into MEFs, after knockdown of endogenous Rab8b with 
siRNA. 
FIG. 10 demonstrates that p53 directly bound to Rab8b 
and that CQ treatment resulted in increased interaction of 
p53 with its binding motif in the Rab8b promoter. FIG. lOA 
depicts CQ induction Rab8b protein and mRNA levels in a 
p53-dependent manner. FIG. 10B demonstrates P53 directly 
binds to its consensus binding site in the Rab8b promoter. 
FIG. lOC demonstrates Par-4 co-localized with Rab8b+ 
vesicles in CQ treated cells. 
FIG. llA demonstrates that treatment of A549 lung can-
cer cells with radiation and CQ has an unexpected greater 
than additive effect in inhibiting growth and proliferation. 
The A549 shPar-4 cells showed reduced radiosensitivity and 
increased growth rate indicating that the action of CQ was 
dependent on Par-4. 
FIG. 11B demonstrates that treatment of Mel 1617 and 
Mel 1617BR melanoma cells with radiation and CQ has an 
unexpected greater than additive effect in inhibiting growth 
and proliferation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Chloroquine (also known as chloroquine phosphate, and 
referred to herein as "CP"), chloroquine diphosphate (CQ), 
and hydroxychloroquine (HCQ or HQ), hereinafter referred 
6 
the growth and/or recurrence of lung and prostate tumors, 
and for inhibiting tumor metastasis, e.g., brain metastasis of 
lung tumors, or bone and lung metastasis of prostate tumors. 
An aspect of the invention described herein is a method 
5 for treating a subject in need thereof with chloroquine (e.g., 
CP, CQ, and/or HCQ), or a salt or a prodrug thereof, and 
other agents that promote Par-4 production by normal cells, 
to increase apoptosis of cancer cells and to reduce the 
metastasis and proliferation and/or survival of cancer cells. 
10 Another aspect of this invention is a method for treating a 
subject in need thereof with a combination of chloroquine, 
or a salt or a prodrug thereof, with curcumin and/or ibupro-
fen to elevate Par-4 production by normal cells, to increase 
apoptosis of cancer cells, to reduce the metastasis and 
15 proliferation and/or survival of cancer cells. 
In an aspect, the present invention includes methods of 
treating cancer cells that respond to exogenously added 
Par-4 but are nonresponsive to chloroquine, or a salt or 
prodrug of chloroquine (ie, cancer cells nonresponsive to 
20 chloroquine will not produce their own Par-4 in response to 
chloroquine). The method comprises contacting a popula-
tion of cells comprising cancer cells that are nonresponsive 
to chloroquine, or a salt or prodrug thereof, and normal cells 
that are responsive to chloroquine, or a salt or prodrug 
25 thereof, with an effective amount of chloroquine, or salt or 
prodrug thereof, wherein treatment with the effective 
amount of chloroquine, or salt or prodrug thereof, kills 
cancer cells, inhibits cancer cell proliferation, cancer cell 
30 
metastasis, and/or recurrence of one or more tumors. 
In a preferred aspect, cancer cells that are nonresponsive 
to chloroquine, or salt or prodrug thereof, are those cancer 
cells where expression of Par-4 by those cancer cells is not 
increased in response to exposure to chloroquine, or a salt or 
prodrug thereof. In a further preferred aspect, normal cells 
35 that are responsive to chloroquine, or salt or prodrug thereof, 
are those normal cells where expression of Par-4 by those 
normal cells is increased in response to exposure to chlo-
roquine or a salt or prodrug thereof. In the context of the 
present invention, a normal cell refers to a non-malignant 
to collectively as "chloroquine", have been safely used as an 
anti-malarial drug for many years. Prior studies have shown 
that chloroquine may be used to increase the effectiveness of 
chemotherapy by co-administering chloroquine with a che-
motherapeutic agent. Although chloroquine is not currently 
considered in the clinic for treatment of primary tumors, a 
number of cell culture and in vivo mouse studies have used 
chloroquine in combination with standard chemotherapeutic 
agents for direct action in tumors. Moreover, although it has 
been reported that chloroquine blocks degradative 
autophagy (Kimura et al. (2013) "Chloroquine in cancer 45 
therapy: a double-edged sword of autophagy" Cancer Res. 
73:3-7), it has not been reported that chloroquine promotes 
autophagy-related secretion (Dupont et al. (2011) 
"Autophagy-based unconventional secretory pathway for 
extracellular delivery of IL-1" EMBO J. 30:4701-11 and; 50 
Jiang et al. (2013) "Secretory versus degradative autophagy: 
unconventional secretion of inflammatory mediators" J 
Innate lmmun. 5(5):471-9). 
40 cell. 
By the present invention, a salt or prodrug of chloroquine 
may include any salt or prodrug with pharmacological 
activity in vitro and/or in vivo that is similar to the phar-
macological activity of CP, CQ, or HCQ as discussed herein. 
Such salts and prodrugs will be readily apparent to the 
skilled artisan and can be readily prepared by the skilled 
artisan based on knowledge in the art. 
The present invention includes a method of killing cancer 
cells, e.g., by inducing apoptosis, or inhibiting cancer cell 
proliferation, cancer cell metastasis, and/or recurrence of 
tumors in a subject comprising administering an effective 
amount of an agent to a subject in need of treatment for 
sufficient time to increase prostate apoptosis responsive 4 
(Par-4) secretion from normal cells in the subject, wherein 
the agent is chloroquine phosphate, chloroquine diphos-
phate, hydroxychloroquine, or a salt or a prodrug thereof, 
and wherein the agent is not administered with a chemo-
therapeutic. 
In the methods of this invention, the chloroquine, or salt 
Disclosed herein is the surprising finding that chloro-
quine, including for example CQ and HCQ, promotes secre- 55 
tion of Par-4 both in vitro and in vivo. Further, treatment of 
normal cells with CQ or HCQ and curcumin and/or ibupro-
fen, resulted in a further increase in the levels of Par-4 
secreted from normal cells as compared to the levels of Par-4 
secreted by cells treated with CQ or HCQ alone. 60 or prodrug thereof, is administered to a subject in need 
thereof in an effective amount, e.g., an amount sufficient to 
increase Par-4 expression and/or secretion level above the 
level of Par-4 expressed, secreted, or both by a normal cell 
prior to administration of the chloroquine or salt or prodrug 
The results disclosed herein demonstrate that the levels of 
Par-4 in conditioned medium from cell cultures treated with 
CQ or HCQ, and the levels of Par-4 in the serum of patients 
treated with CQ or HCQ cause robust apoptosis of cancer 
cells, e.g., lung and prostate cancer cells. The enhanced 
levels of Par-4 induced by CQ or HCQ treatment, with or 
without curcumin and/or ibuprofen, are useful for inhibiting 
65 thereof. In another aspect, an effective amount of chloro-
quine, or salt or prodrug thereof, is an amount sufficient to 
increase apoptosis of cancer cells, and/or reduce prolifera-
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cularly, parenterally, rectally, etc. For example, the chloro-
quine or chloroquine salt or prodrug thereof may be admin-
istered orally to the subject in any pharmaceutically 
acceptable form, e.g., in the form of a tablet, a capsule, a 
tion and/or reduce metastasis of cancer cells in the subject. 
Preferably, the chloroquine or salt or prodrug thereof is 
administered in an amount that induces apoptosis in cancer 
cells while having little or no detrimental effect on kidney 
function in the subject. 
By way of non-limiting example, an effective amount of 
chloroquine contacted with cells may include for example 
about 200 nM to about 10004, about 150 nM to about 75 
µM, about 100 nM to about 50 µM, about 100 nM to about 
5 syrup, or an elixir, or infused or injected by, e.g., an 
intraperitoneal or intravenous or intramuscular route, and in 
an amount sufficient to increase the levels of Par-4 in the 
subject, preferably to a level that is sufficient to kill the 
40 µM, about 100 nM to about 35 µM, about 100 nM to 10 
about 30 µM, about 100 nM to about 25 µM. 
In various embodiments, an effective amount of chloro-
quine is contacted with cells for at least about 2 hours, at 
least about 5 hours, at least about 10 hours, at least about 16 
hours, at least about 18 hours, at least about 20 hours, at least 15 
about 24 hours, at least about 2 days, at least about 3 days, 
at least about 5 days, at least about a week, at least about 2 
weeks, or more than 2 weeks. 
By way of further non-limiting example, an effective 
amount of chloroquine administered to a subject in need 20 
thereof may include about 50-2000 mg daily, about 100-
1500 mg daily, about 150-1200 mg daily, about 200-1200 
mg daily, about 100 mg daily, about 200 mg daily, about 300 
mg daily, about 400 mg daily, about 500 mg daily, about 750 
mg daily, about 1000 mg daily, about 1200 mg daily or more 25 
than about 1200 mg daily. 
In various embodiments, an effective amount of chloro-
quine is administered to a subject in need thereof for 1 day, 
for 2 days, for 5 days, for about 1 week, for about 2 weeks, 
cancer cells, e.g., induce apoptosis in cancer cells, and/or 
inhibit proliferation and/or inhibit metastasis. Pharmaceuti-
cally acceptable forms may also comprise one or more 
pharmaceutically acceptable carriers, diluents, or excipients. 
Pharmaceutically acceptable carriers, diluents, or excipients 
are known in the art such as those described in, for example, 
Remington's Pharmaceutical Sciences, Mack Publishing 
Co. (A. R. Gennaro edit. 1985), incorporated herein by 
reference. 
The cancer cells and cancers that are treated may be of 
any type, including but not limited to, e.g., prostate cancer, 
breast cancer, skin cancer (e.g., melanoma), lung cancer, 
and/or any combination thereof. In an embodiment, cancer 
does not include any type of renal cancer. In a further 
embodiment, cancer does not include renal cell carcinoma 
but may include other types of renal cancer, such as for 
example transitional cell cancer of the renal pelvis (TCC) or 
Wilms' tumor in children. 
The cancer may comprise cancer cells that are hormone 
responsive or hormone non-responsive or the cancer may be 
one that is susceptible or refractory to one or more chemo-
therapeutic treatment. For example, the cancer may be a 
prostate, or breast cancer, e.g., an androgen independent 
prostate cancer cells, a breast cancer that expresses no or low 
levels of Par-4, or a highly aggressive, estrogen receptor-
negative, high-grade (grade 3) or basal-like tumor. The 
for at least about 1 month, for at least about 2 months, for 30 
at least about 3 months, for at least about 6 months, for at 
least about 8 months, for at least about 1 year, or for more 
than 1 year. It is understood that the duration of treatment 
will depend upon the stage of cancer and whether the cancer 
has gone into remission. 35 cancer may also be a lung cancer, e.g., non-small cell lung 
cancer, small cell lung cancer and lung carcinoid tumor, that 
is sensitive to or refractory to treatment with a chemo-
therapy. The cancer may be a malignant melanoma and may 
The actual amount encompassed by the term effective 
amount will depend on the route of administration, the type 
of subject being treated, and the physical characteristics of 
the specific subject under consideration, e.g., their age, 
weight, severity of disease, co-morbidities. These factors 40 
and their relationship to determining this amount are well 
known to skilled practitioners in the medical, and other 
related arts and one of skill in the art can readily determine 
the appropriate effective dose of chloroquine to be admin-
istered to a subject to achieve the desired levels of Par-4 45 
secretion. Likewise, the dosing schedule may be readily 
determined by the skilled artisan. 
As chloroquine has been used in the art for the treatment 
include for example superficial spreading melanoma, nodu-
lar melanoma, or lentigno maligna melanoma or desmoplas-
tic melanoma. 
In an embodiment of the present invention, a cancer cell 
or tumor is located in a highly vascularized tissue. In the 
context of the present invention, a highly vascularized tissue 
includes any tissue with better than average vascularization. 
For example, without limitation, highly vascularized tissue 
of malaria, one of skill in the art could readily modify known 
pharmaceutical formulations of chloroquine used in the 50 
treatment of malaria such that they are suitable for use in the 
methods described herein. 
includes blood, lung, liver, skin, or kidney. In an embodi-
ment of the present invention, a cancer cell or tumor is 
located in a highly vascularized tissue that does not include 
a kidney. 
A cancer cell or cancer that is located in a highly vascu-
larized tissue may have originated in that or another highly 
vascularized tissue or may have traveled to a highly vascu-
larized tissue from any other tissue by metastasis. In an 
In some aspects, the chloroquine may be administered in 
a single dose and may be administered with or without 
another agent including, e.g curcumin, ibuprofen, ionizing 
radiation, a chemotherapeutic agent, or any combination 
thereof. In some aspects of this invention, the chloroquine 
with or without another agent may be is administered in 
multiple doses. Dosing may be once, twice, three times, four 
times, five times, six times, or more than six times per day. 
In some cases, continuous dosing is achieved and main-
tained as long as necessary. Dosing may also be formulated 
for extended release. 
The chloroquine and chloroquine salts or prodrugs 
thereof, with or without curcumin and/or ibuprofen may be 
administered to the subject by any means currently used in 
the art, e.g., orally, subcutaneously, intravenously, intramus-
55 embodiment of the present invention, the cancer cell is p53 
deficient. A p53-deficient cancer cell may have a p53-
deficient genotype or phenotype. For the purposes described 
herein a p53-deficient cancer cell has, e.g., a mutation within 
the p53 gene, e.g., insertion(s ), deletion(s) of part or all of 
60 the gene, substitution(s) etc. such that no p53 or a mutant 
p53, e.g., one that does not bind DNA effectively, is pro-
duced. 
Preferably the chloroquine, or salt or prodrug thereof, is 
not co-administered with a chemotherapeutic, particularly a 
65 chemotherapeutic used in the treatment of prostate or lung 
cancer, e.g., carmustine, Akt inhibitor MK2206, sul-
foraphane, or PI! 03, cisplatin-etoposide, cyclophosph-
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amide, and fluroruracil. As used herein, chemotherapeutics 
does not include curcumin and/or ibuprofen. 
10 
embodiments, the chloroquine and curcumin or ibuprofen, 
or both, may be administered to the subject in need thereof 
for 1 day, for 2 days, for 5 days, for about 1 week, for about 
2 weeks, for at least about 1 month, for at least about 2 
By the methods of the present invention, the chloroquine 
may optionally be administered with an effective amount of 
curcumin, ibuprofen or both curcumin and ibuprofen. An 
effective amount of curcumin and/or ibuprofen for use in the 
methods described herein is the amount of curcumin and/or 
ibuprofen administered to the subject in need thereof that is 
sufficient to increase expression and/or secretion of Par-4 by 
the normal cells of the subject. Preferably the curcumin 
and/or ibuprofen are administered to the subject in an 
amount and for a sufficient time to enhance the production 
and/or secretion of Par-4 induced by treatment with chlo-
roquine or a chloroquine salt or prodrug thereof alone. 
5 months, for at least about 3 months, for at least about 6 
months, for at least about 8 months, for at least about 1 year, 
or for more than 1 year. 
The curcumin and/or ibuprofen may be co-administered 
to the subject with the chloroquine or chloroquine salt or 
10 prodrug thereof. For the purposes of this invention, co-
administered or co-administering or co-administration refers 
to the administration of two or more agents or therapies 
(e.g., radiation therapy) to a subject in any manner in which 
the pharmacological effects of the agents or therapies are 
By way of non-limiting example, an effective amount of 
curcumin contacted with cells may include for example 
about 0.1-100 µM, about 0.2-50 µM, about 0.5-20 µM, about 
1-10 µM, about 1 µM, about 2 µM, about 3 µM, about 4 µM, 
about 5 µM, about 6 µM, about 7 µM, about 8 µM, about 9 
µM, about 10 µM, about 15 µM, about 20 µM, about 25 µM, 
about 30 µM, about 35 µM, about 40 µM, about 50 µM, 
about 75 µM, about 100 µM, about 120 µM, about 150 µM, 
about 180 µM, about 200 µM, about 300 µM, about 400 µM, 
about 500 µM, about 1000 µM, or more than about 1000 µM. 
15 manifest in the subject at the same time. Co-administration 
does not require that the agents or therapies be administered 
in a single pharmaceutical composition, in the same dosage 
form, at the same time, or by the same route of administra-
tion. The effects of the agents or therapies need not manifest 
20 themselves at the same time. The effects need only be 
overlapping for a period of time and need not be coexten-
s1ve. 
The methods of the present invention may also include 
treatment with chloroquine and an effective amount of 
ionizing radiation. Ionizing radiation has been used in the 
treatment of a variety of cancers, including melanoma (Khan 
et al. Onco Targets Ther. 2011; 4: 137-148). An effective 
amount of ionizing radiation may include any amount that is 
sufficient to kill cancer cells, inhibit cancer cell proliferation, 
By way of further non-limiting example, an effective 25 
amount of curcumin administered to a subject in need 
thereof may include, e.g., a daily dose of about 100 mg to 
about 1500 mg, or about 100 mg to about 1200 mg, or about 
500 mg to about 1000 mg, or about 250 to about 500 mg, or 
about 250 mg to about 1000 mg. 
By way of non-limiting example, an effective amount of 
ibuprofen contacted with cells may include for example 
about 100-2500 µM, about 200-2000 µM, about 500-1500 
µM, about 500-1000 µM, about 500-750 µM, about 750-
1000 µM, about 250 µM, about 350 µM, about 500 µM, 35 
about 600 µM, about 700 µM, about 750 µM, about 800 µM, 
about 850 µM, about 1000 µM, about 1250 µM, about 1500 
µM, about 1750 µM, about 2000 µM, or more than about 
2000 µM. 
30 cancer cell metastasis, and/or recurrence of one or more 
tumors. In an embodiment, an effective amount is about 1-5 
Gy of radiation, 2-4 Gy of radiation, or about 2 Gy, about 3 
Gy, about 4 Gy, or about 5 Gy of radiation. An effective 
By way of further non-limiting example, an effective 40 
amount of ibuprofen administered to a subject in need 
thereof may include, e.g., a daily dose of about 200 to about 
400 mg/dose every 8 hours, or about 600 mg/day to about 
1200 mg/day, about 1000-about 3200 mg/day, about 1500-
about 3000 mg/day, about 1800-about 2500 mg/day, about 45 
1200-about 2000 mg/day, about 2500-about 3200 mg/day, 
about 400 mg/day, about 600 mg/day, about 800 mg/day, 
about 1000 mg/day, about 1200 mg/day, about 1400 mg/day, 
about 1600 mg/day, about 1800 mg/day, about 2000 mg/day, 
about 2200 mg/day, about 2400 mg/day, about 2600 mg/day, 50 
about 2800 mg/day, about 3000 mg/day, or about 3200 
mg/day. 
An effective amount of chloroquine and curcumin or 
ibuprofen, or both, are contacted with cells for sufficient 
time to increase and/or maintain an elevated level of 55 
secreted Par-4 from the cells. In various embodiments, an 
effective amount of chloroquine and curcumin or ibuprofen, 
or both, are contacted with cells for at least about 2 hours, 
at least about 5 hours, at least about 10 hours, at least about 
16 hours, at least about 18 hours, at least about 20 hours, at 60 
least about 24 hours, at least about 2 days, at least about 3 
days, at least about 5 days, at least about a week, at least 
about 2 weeks, or more than 2 weeks. 
An effective amount of chloroquine with curcumin or 
ibuprofen, or both, is administered to a subject in need 65 
thereof for sufficient time to increase and/or maintain an 
elevated level of secreted Par-4 in the subject. In various 
amount of ionizing radiation will be apparent to the skilled 
artisan, and in a preferred embodiment, is less than the 
amount of ionizing radiation required to kill cancer cells, 
inhibit cancer cell proliferation, cancer cell metastasis, and/ 
or recurrence of one or more tumors in the absence of 
treatment with chloroquine. 
An effective amount of chloroquine may be co-adminis-
tered with the ionizing radiation treatment. Improved effec-
tiveness of the radiation therapy with administration of 
chloroquine may be manifested as an increase in cancer cell 
killing, e.g., cancer cell apoptosis, inhibited proliferation of 
cancer cells, or inhibited metastasis of cancer cells, as 
compared to similar subjects in need thereof treated with the 
same amount of ionizing radiation but without chloroquine 
treatment. The improved effectiveness of the radiation 
therapy with administration of chloroquine may alterna-
tively or additionally be manifested by achieving cancer cell 
killing, e.g., cancer cell apoptosis, inhibited proliferation of 
cancer cells, or inhibited metastasis of cancer cells, with 
reduced amounts of ionizing radiation than are historically 
required to achieve such anti-cancer effects. In an embodi-
ment, the effects of chloroquine treatment and ionizing 
radiation are unexpectedly more than additive. 
A subject in need of treatment is a subject who has cancer, 
a subject who has been treated for a cancer and is in 
remission or cancer free, or a subject having a recurrent 
cancer. The cancer may be any cancer, including but not 
limited to, e.g., prostate, breast, skin ( e.g., melanoma), 
and/or lung cancer, or any cancer disclosed herein. The 
cancer may be an androgen independent prostate cancer, a 
breast cancer that expresses no or low levels of Par-4, a 
breast cancer that is highly aggressive, estrogen receptor-
negative, high-grade (grade 3) or basal-like tumor, or a 
non-small cell lung cancer, a small cell lung cancer, or a lung 
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carcinoid tumor. The cancer may be a melanoma, e.g., 
superficial spreading melanoma, nodular melanoma, lenti-
gno maligna melanoma, or desmoplastic melanoma. A sub-
ject in need of treatment may also include a subject in need 
of prophylactic treatment, where a subject in need of pro- 5 
phylactic treatment would be, e.g., a subject who does not 
currently have a cancer but has been determined to be at 
higher risk of developing a cancer, particularly a prostate, 
breast, skin, or lung cancer or any cancer described herein, 
as compared with the risk of the general population of 10 
developing that cancer. 
Also an aspect of this invention includes methods for 
reducing the recurrence of a cancer comprising administer-
ing chloroquine, or a chloroquine salt or prodrug thereof, 
preferably without a chemotherapeutic agent, to a subject in 15 
need thereof in an amount sufficient to reduce the recurrence 
of a cancer in the subject. In the methods described herein, 
the chloroquine or a chloroquine salt or prodrug thereof may 
be administered to the subject in need thereof in combina-
tion with another agent that increases the production and/or 20 
secretion of Par-4. In the methods described herein, chlo-
roquine or a chloroquine salt or prodrug thereof may be 
administered to the subject in need thereof in combination 
with an effective amount of curcumin and/or ibuprofen. 
Another aspect of this invention is a method for prophy- 25 
lactically reducing the risk of a subject developing cancer 
comprising administering chloroquine, or a chloroquine salt 
or a prodrug thereof, to a subject in need thereof to elevate 
Par-4 expression from normal cells to a level that enhances 
apoptosis of cancer cells. Still another aspect of this inven- 30 
tion is a method for prophylactically reducing the risk of a 
subject developing cancer comprising administering chlo-
roquine, or a salt or prodrug thereof, in combination with 
curcumin and/or ibuprofen to a subject in need thereof to 
elevate Par-4 expression from normal cells to a level that 35 
enhances apoptosis in cancer cells. 
12 
or actin. CollAl served as a loading control for protein 
secretion, as it is generally unchanged in response to the 
treatments. The samples were also subjected to SDS/PAGE 
and Coomassie blue staining to determine albumin levels in 
serum from the CM as another loading control. The results 
are presented in FIG. 1. 
CQ caused dose-dependent secretion of Par-4 in the CM 
from wild type (p53+/+) MEFs, as well as normal human 
prostate stromal cells (PrSC) and epithelial cells (PrEC), and 
normal human lung fibroblasts (HEL) and epithelial cells 
(HBEC) (FIG. lA). CQ neither induced Par-4 secretion in 
prostate cancer cells (LNCaP, C4-2B, DU145 and PC-3) nor 
in lung cancer cells (H460, A549) (FIG. 18). 
Immunocompetent mice were injected intraperitoneally 
with a single dose (50 mg/kg body weight) of CQ or a 
control vehicle and 24 hours later serum samples were 
collected and tested for systemic levels of Par-4. Relative to 
vehicle treatment, CQ induced robust elevation of Par-4 in 
mouse serum (FIG. lC). 
Serum samples were collected from renal cell carcinoma 
patients who were given safe oral doses ( 400 mg daily for 
2-weeks) of HCQ pre-operatively at the University of Pitts-
burgh, as part of a clinical trial in 2010-2011. Pre-HCQ 
treatment and post-HCQ treatment serum samples were 
collected and frozen. In 2013-2014, they were processed by 
Western blot analysis. Patients who were taking HCQ prior 
to surgery showed elevated levels of Par-4 relative to 
pre-treatment levels (FIG. lD). 
Example 2 
The results presented herein demonstrate CQ-inducible 
Par-4 secretion in CM of normal cells causes apoptosis in 
cancer cell cultures. Furthermore, the results demonstrate 
that the serum from a renal cell carcinoma patient who 
showed-3-fold induction of Par-4 following HCQ treatment 
also induces ex vivo apoptosis of various normal and cancer 
cells. 
Briefly, MEFs from Par-4_1_ or Par-4+/+ mice were treated 
It is understood that the methods of this invention in some 
embodiments may include a step of selecting a subject in 
need thereof, by identifying a subject who has a cancer(s) 
described herein, or who has been treated for such cancer(s) 
and is in remission or cancer free, or has a recurrent 
cancer( s ), or is in need of prophylactic treatment, and then 
administering an effective amount of chloroquine with or 
without an effective amount of curcumin, ibuprofen, or 
ionizing radiation, or combinations thereof, to such subject 
as described herein. 
40 with vehicle (v) or CQ (20 µM) for 24 h, and their CM was 
transferred to normal (HEL) or p53-wild type lung cancer 
cells (H460 and A549), p53-deficient cancer lung cancer 
cells (HOP92 and H1299), and p53-deficient prostate cancer 
cells (PC-3 and DU145). After 24 h, the cells were subjected 
EXAMPLES 
Example 1 
The Results Presented Herein Demonstrate that Chloro-
quine Induces Secretion of Par-4 from Normal Cells. 
Various normal mouse or human cell lines, mouse embry-
onic fibroblasts (MEFs, early passage 4 or 5), human pri-
mary prostate fibroblast cells (PrSC), human bronchial epi-
thelial cells (HBEC), human primary prostate epithelial cells 
(PrEC), human lung embryonic fibroblasts (HEL), human 
prostate cancer cell lines, androgen-dependent LNCaP cells, 
and androgen-independent (castration-resistant) C4-2B, 
DU145 and PC-3 cells and human lung cancer cell lines 
H460 and A549 were treated with 1, 10, 20, 25, 50 or 100 
µM of chloroquine diphosphate (CQ) or with a vehicle (V) 
control for 24 h. 
45 to immunocytochemistry (ICC) for active caspase-3 and 
apoptotic cells were scored under a fluorescent microscope. 
The results are depicted in FIGS. 2A-F. An asterisk (*) 
indicates statistical significance (P<0.001) by the Student's 
t-test. 
50 Prostate cancer cells PC-3, and lung cancer cells H460, 
H1299, HOP92, KP7B cells, but not normal HEL cells were 
sensitive to apoptosis when co-cultured with Par-4+/+ MEFs, 
but not Par-4_1_ MEFs, treated with CQ. Prostate cancer 
cells DU145 or lung cancer cells A549 that are resistant to 
55 apoptosis by Par-4 were, as expected, resistant to apoptosis 
by the Par-4 secreted from CQ treated Par-4+/+ MEFs and 
served as an internal control (FIG. 2A). 
Cancer cell apoptosis was also induced by the CM of 
Par-4+/+ MEFs treated with CQ, and the apoptotic activity of 
60 the CM was inhibited by the Par-4 antibody (which neutral-
izes Par-4 in the CM) or by the GRP78 antibody, which is 
expected to inhibit binding of Par-4 to GRP78 on the cancer 
cell surface (FIG. 2B). 
The conditioned medium (CM), as well as the whole-cell 65 
lysates were subjected to Western blot analysis with the 
antibodies specific for Par-4, Collagen (CollAl), albumin, 
Aliquots of CM from wild type MEFs treated with CQ 
were incubated withA549 cells pretreated with PS-1145 (10 
µM) or vehicle (v). After 24 h, the cells were scored for 
apoptosis. A549 cells treated with the NF-KB-inhibitor 
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PS-1145, which elevates Par-4 receptor GRP78 on the 
cancer cell surface (Burikhanov et al. "Novel mechanism of 
apoptosis resistance in cancer mediated by extracellular 
PAR-4". Cancer Res. 73: 1011-1019, 2013. PMCID: 
PMC3549021), were sensitized to apoptosis by the Par-4 5 
secreted in the CM from MEFs in response to CQ treatment 
(FIG. 2C). 
The serum from a renal cell carcinoma patient who 
showed-3-fold induction of Par-4 following HCQ treatment 
14 
mice but not the serum from CQ-treated Par-4_1_ mice 
induced ex vivo apoptosis in LLCl cells, and this action of 
the serum was neutralized by the Par-4 or GRP78 antibody 
but not the control antibody (FIG. 3C). These results dem-
onstrate that basal levels of Par-4 in wild type mice can 
prevent the establishment and growth of cancer cells, and 
that Par-4 levels elevated in response to CQ further inhibit 
tumor growth. Collectively, these findings indicate that 
Par-4 levels secreted by normal cells in cell culture, mice 
and patients in response to CQ are adequate to cause ex vivo 
apoptosis of cancer cells and to inhibit the growth of tumors 
m mice. 
Example 4 
The experimental results presented herein demonstrate 
that CQ induces Par-4 secretion by a p53-dependent mecha-
nism, that CQ inhibits NF-KB activity, but not AP! activity, 
and inhibits VACA expression. Furthermore, the results 
demonstrate that CQ induces Par-4 section by a BFA sen-
sitive mechanism. 
Wild type or p53-null MEFs were treated with CQ or 
Nutlin-3a, which is known to induce Par-4 secretion by a 
p53-dependent mechanism. CQ caused robust induction of 
( 400 mg daily dose of HCQ for 2 weeks) was also assayed 10 
for induction of ex vivo apoptosis of various normal and 
cancer cells. Aliquots of pre-HCQ or post-HCQ treatment 
serum samples from the patient were transferred to cancer 
cell cultures (20% final concentration). After 24 h, the cells 
were scored for apoptosis by ICC for active caspase-3. Fetal 15 
bovine serum (FBS, 10%) was used as an additional control. 
An asterisk(*) indicates statistical significance (P<0.001) by 
the Student's t-test. The cancer cells, PC-3, H460, HOP92, 
and H1299, underwent apoptosis with aliquots ofpost-HCQ 
treatment serum relative to the background apoptosis level 20 
produced by aliquots of pre-HCQ treatment serum (FIG. 
2D). Importantly, apoptosis of cancer cells by post-treatment 
serum from the patient was neutralized by the Par-4 antibody 
(P) or GRP78 antibody (G), but not by control antibody (C) 
(FIG. 2E). 25 Par-4 secretion in wild type MEFs but not in p53-null MEFs 
(FIG. 4A). In addition, CQ induced p53 expression in wild 
type MEFs (FIG. 4A). These data suggested that p53 func-
tion was required for Par-4 secretion in response to CQ. 
Moreover, the serum from mice treated with a single dose 
of CQ but not the serum from control vehicle-treated mice 
induced ex vivo apoptosis of cancer cells, and this activity 
was neutralized by the Par-4 antibody or GRP78 antibody 
(FIG. 2F). Together, these findings indicate that CQ-induced 30 
Par-4 expression levels, in the CM of cell cultures or in the 
serum of mice, are adequate to trigger apoptosis of cancer 
cells. 
VACA, an infl=ation associated protein, binds to 
Par-4 and sequesters it, thereby preventing Par-4 secretion. 
VACA expression is inhibited by p53 but is induced by 
NF-KB-activation. To assess CQ suppression of NF-KB 
activity and VACA expression, normal and cancer cells 
were transfected with reporter controls for NF-KB or AP! 
Example 3 
The results presented herein demonstrate that CQ induces 
tumor growth inhibition by a Par-4-dependent mechanism. 
The results also demonstrate that Par-4 in serum from 
35 and then treated with CQ or vehicle for 24 h. In addition, 
MEFs were pre-treated with BFA (10 µg/ml) or vehicle for 
30 minutes and further treated with CQ (50 µM) or vehicle 
(V) for 5 h. The CM and lysates were examined by Western 
CQ-treated mice induces ex vivo apoptosis in LLCl cells. 40 
blot analysis with the indicated antibodies. 
CQ inhibited NF-KB activity, but not AP! activity, in 
normal cells but not in cancer cells (FIG. 4B). Moreover, CQ 
inhibited the expression of VACA in mouse embryonic 
fibroblasts (MEF), and human embryonic lung fibroblasts 
(HEL), but not p53 null MEFs (FIG. 4C). CQ-induced Par-4 
Aliquots of culture media (CM) from Par-4_1_ or Par-4+/+ 
MEFs treated with CQ (20 µM) or vehicle (v) were incu-
bated with LLCl cells for 24 h, and the cells were scored for 
apoptosis. Moreover, aliquots of CM from wild type MEFs 
treated with CQ or vehicle were incubated with control (C) 
antibody (Ab), Par-4 (P) Ab or GRP78 (G) Ab and then 
transferred to H460 cells. After 24 h, the cells were scored 
for apoptosis. *P<0.0001 by the Student's t-test. CM from 
Par-4+/+ MEFs but not from Par-4_1_ MEFs treated with CQ 
induced apoptosis of LLCl cells and this apoptotic activity 50 
in the CM was inhibited by the Par-4 (P) Ab or GRP78 (G) 
Ab (FIG. 3A). 
45 expression was inhibited by BFA (FIG. 4D). Collectively, 
these studies indicate that CQ induces Par-4 secretion by the 
classical secretory pathway that is dependent on VACA 
suppression by p53 and by inhibition of NF-KB activity. 
In a model of tumor cell metastasis, LLCl cells were 
injected intravenously into Par-4+/+ (wild type) or Par-4_1_ 
mice, and then CQ (25 mg/kg body weight) was injected 55 
once daily for 5 consecutive days. Tumor growth was 
examined over a 21-day period. 
The serum from Par-4+/+ mice but not Par-4_1_ mice 
injected with CQ showed robust Par-4 secretion relative to 
the serum from vehicle-treated mice (FIG. 3B). Importantly, 60 
luciferase imaging as well as examination of the mouse 
tumors indicated strong inhibition (P<0.001 by the Student's 
t test) of tumor growth in the lungs of CQ-treated Par-4+/+ 
mice. On the other hand, Par-4_1_ mice showed a signifi-
cantly higher number oflung nodules relative to the Par-4+/+ 65 
mice, and CQ failed to inhibit tumor growth in Par-4 _1_ mice 
(FIG. 3B). Moreover, the serum from CQ-treated Par-4+/+ 
Example 5 
A. Vascularized/Metastatic Lung Cancer Model 
To test directly the role of Par-4 secreted in response to 
CQ, the ability of Par-4 neutralizing antibody to block 
CQ-induced inhibition of LLCl-derived lung tumor nodules 
was examined. In an experimental metastasis model, athy-
mic nu/nu mice were injected with 200xl05 LLCl cells 
intravenously, and after 24 h, the mice were injected with 
vehicle or CQ (i.p., 25 mg/kg body weight) once daily for 
five consecutive days. Animals injected with CQ were also 
injected within 2 h with either the control IgG or Par-4 
polyclonal antibody (20 µg/injection). Each group included 
10 mice. After 21 days, the lungs were perfused, stained with 
India ink (FIG. 6A upper panel) and the tumor nodules were 
scored (FIG. 6ALowerpanel). *P=0.007 by Student's t-test. 
As seen in FIG. 6A, relative to vehicle control, CQ 
induced >85% inhibition of tumor nodules in the lungs of 
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MEF) or cancer (LLCl, H460, A549, PC-3) cells were 
co-transfected with luciferase (luc) reporter construct for 
NF-KB, AP!, or empty luc construct and ~-galactosidase 
expression construct and treated for 18 h with CQ (25 µM) 
nude mice in the presence of control IgG, but only ca. 40% 
inhibition of lung tumor nodules in the presence of Par-4 
antibody. These results indicated that CQ-inducible secre-
tion of Par-4 plays a significant role in inhibition of lung 
tumor nodules in the experimental metastasis model. 
B. Non-Vascularized Cancer Model 
To determine whether CQ inhibits the growth of tumors in 
tissue that is not highly vascularized, 4xl05 H460 or LLCl 
cells were injected subcutaneously in nude (nu/nu) mice to 
generate tumors in the flanks. When the tumors had grown 
5 or vehicle (V). Luciferase activity was analyzed in the cell 
lysates and normalized with respect to the corresponding 
~-galactosidase activity. *P<0.001 by the Student's t-test. 
(FIG. 4B). Moreover, CQ inhibited the expression of VACA 
and NF-KB-regulated genes cIAPl and XIAP in a p53-
10 dependent manner (FIG. 7B). 
By contrast, in cancer cells that failed to show induced 
Par-4 secretion in response to CQ, CQ neither induced p53 
nor did it inhibit NF-KB activity (FIG. 4B), and CQ con-
sistently failed to downregulate VACA (FIG. SD). Collec-
to ca. 200 mm3 volume (indicated by arrow), the mice (10 
per group) were injected IP with CQ (25 mg/kg body 
weight) or vehicle once daily throughout the experiment, 
and tumor growth was measured with calipers over period of 
the experiment to calculate tumor volume. In contrast to 
Example SA, yet consistent with the findings of Xia et al. 
(2014) Sci Trans Med 6: 161-182, CQ failed to inhibit the 
growth of LLCl- or H460-derived tumor xenografts in the 
flanks of mice (FIG. 6B). Without wishing to be bound by 
theory, the lack of response may be due to the inability of 20 
Par-4 and/or CQ to reach the tumor microenvironment 
owing to inadequate neovascularization in the subcutaneous 
tumors. 
15 tively, these studies indicated that similar to our findings 
with Nutlin-3a (Burikhanov et al., 2014a), CQ-induced 
Par-4 secretion by the classical secretory pathway that is 
dependent on VACA suppression by p53 and by inhibition 
of NF-KB activity. 
Collectively, the findings of Examples SA and 5B indi-
cated that Par-4 levels secreted by normal cell cultures, mice 25 
and patients in response to CQ were adequate to cause ex 
vivo apoptosis of cancer cells and to inhibit the growth of 
metastatic lung tumor nodules in mice. 
Example 7 
The results presented herein demonstrate Rab8b is a novel 
target of p53 critical for Par-4 secretion from normal cells. 
Testing was performed to determine whether the expres-
sion of Rab genes containing putative p53 binding sites in 
their promoter region were essential for Par-4 secretion. 
These studies indicated that Rab8b-null MEF cells, but not 
Rab8a-null MEF cells, failed to show induction of Par-4 
Example 6 
The results presented herein demonstrate induction of 
Par-4 secretion by CQ required components of the classical 
secretory pathway 
30 secretion by CQ (FIG. 9A). CQ-induced Rab8b expression 
but not Rab8a expression in wild type MEFs (FIG. 9A). CQ 
also induced Rab8b in normal human cells but not in cancer 
cells (FIG. 9D). It was determined that Rab8b-null MEF 
Wild type or p53-null MEFs were treated with CQ, 35 
Arylquin-1, or Nutlin-3a. Nutlin-3a, an inhibitor of MDM2 
binding to p53 (Vassilev et al., 2004 Science 303:844-848), 
induced Par-4 secretion in a p53-dependent manner (FIG. 
7 A). Similarly, CQ and Arylquin-1 caused robust induction 
of Par-4 secretion in wild type MEFs, but not in p53-null 40 
MEFs (FIG. 7A). Moreover, CQ induced p53 activation, as 
judged by the increase in phospho-S15-p53 and total p53 
expression in wild type MEFs (FIG. 7A right top panel). 
Activation of p53 by CQ was accompanied by increased 
p53-dependent transcription (FIG. SA), and upregulation of 45 
p53-responsive genes p21 and PIG3 in MEFs and normal 
mouse lung tissues (FIG. 7B and FIG. SB, respectively). 
Although CQ caused an increase in total Par-4 protein levels 
(see FIGS. 1 and 4), it did not induce Par-4 at the RNA level 
(FIG. SC), implying that Par-4 protein levels were elevated 50 
by CQ induced translational/posttranslational regulation. 
Collectively, these data suggested that p53 was activated by 
CQ, and that p53 function was required for induction of 
Par-4 secretion by CQ, but not for elevation of intracellular 
Par-4 protein levels. These data are consistent with ChIP 55 
data and an observation that the Par-4 (PAWR) gene lacks 
p53-consensus binding sites for transcriptional regulation by 
p53 (Burikhanov et al. (2014a)). 
cells were not deficient in p53 induction in response to CQ. 
Moreover, the effect of transiently transfecting Rab8b-null 
MEFs with mouse Rab8b expression construct or vector for 
control was assayed and it was noted that CQ induced Par-4 
secretion in Rab8b reconstituted cells (FIG. 9B). Knocking 
down Rab8b with siRNAs resulted in inhibition of Par-4 
secretion in the CM, as judged by Western blot analysis 
(FIG. 9C), and the reintroduction ofGFP-Rab8b into MEFs, 
after knockdown of endogenous Rab8b with siRNA, rescued 
Par-4 secretion (FIG. 9D). 
The guardian of the genome, p53 binds to a consensus 
motif5'-PuPuPuC4(A/T)(A/T)G7PyPyPy [0-13] PuPuPuC4 
(A/T)(A/T)G7PyPyPy-3'(SEQ ID NO: 1) (where purines at 
4 and 7 position are critical) in the promoter of genes that it 
transcriptionally regulates (El-Deiry et al., 1992 Nat Genet 
1 :45-49). Putative p53-binding sites 5'-GGGGCACGC-
CCGAGGCTCCCC-3' SEQ ID NO: 2 on human chromo-
some 15 (corresponding to nucleotides at position 
63481874-63481894) and 5'-GGAGAGCCGCGGGCGT-
GCCT-3' SEQ ID NO: 3 on mouse chromosome 9 (corre-
sponding to nucleotides at position 66767671 to 66767690) 
were noted in the promoter regions upstream of the tran-
scription start site of human and mouse Rab8b, respectively 
(http://www.sabiosciences.com/chipqpersearch.php ). CQ 
enhanced Rab8b protein levels in p53 wild type cells but not 
in p53-null cells, and quantitative, real-time PCR studies 
indicated that CQ induced Rab8b mRNAin a p53-dependent 
manner (FIG. lOA). 
It was previously shown that VACA, an inflammation-
associated protein, bound to Par-4, sequestered it in the ER, 60 
and thereby prevented Par-4 secretion (Burikhanov et al., 
2013 Cancer Res 73, 1011-1019). VACA expression was 
inhibited by p53 but was induced by NF-KB activation. 
Activation of p53 or inhibition of NF-KB activation pro-
moted Par-4 secretion (Burikhanov et al., 2013). 
To determine if p53 directly binds to this consensus 
binding motif within the Rab8b promoter in order to induce 
Rab8b expression, MEF cells were treated with CQ or 
65 vehicle and subjected the DNA to chromatin-immunopre-
cipitation analysis with p53 antibody (Ab) or control IgG 
antibody. As seen in FIG. lOB, relative to vehicle, treatment 
Testing was done to determine whether CQ suppressed 
NF-KB activity and VACA expression. Normal (HEL and 
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with CQ resulted in elevated levels of chromatin immuno-
precipitation of the p53-consensus motif in Rab8b. By 
contrast, either the control IgG antibody used along with 
primers near the p53 binding site in the Rab8b promoter or 
the p53 antibody used along with primers corresponding to 5 
the region in the GAPDH promoter or Par-4 gene, where p53 
was not expected to bind, failed to show chromatin immu-
noprecipitation (FIG. lOB). These findings indicated that 
p53 directly bound to Rab8b and that CQ treatment resulted 
in increased interaction of p53 with its binding motif in the 10 
Rab8b promoter. 
An immunocytochemical (ICC) analysis was performed 
to determine the localization of Par-4 in Rab8b coated 
vesicles. Relative to vehicle treatment, CQ induced an 
increase in the co-localization of Par-4 with Rab8b contain- 15 
ing vesicles, and BFA prevented Par-4 from entering the 
Rab8b vesicles (FIG. lOC). Together, these findings indi-
cated that the Rab8b gene was induced in a p53-dependent 
manner and that Rab8b was essential for CQ-induced secre-
tion of Par-4 by the BFA-sensitive post-Golgi pathway to 20 
plasma membrane. 
Example 8 
The results presented herein demonstrate chloroquine 25 
sensitizes cancer cells to radiation therapy. 
A549 lung cancer cells stably transfected with either 
non-specific control shRNA or Par-4 shRNA were exposed 
to 0, 2, 4 Gy of radiation respectively and treated with 10 µM 
or 20 µM CQ. FIG. llA demonstrates treatment with radia- 30 
tion and CQ has an unexpected greater than additive effect 
18 
cantly improves the secretion of Par-4 achieved by treatment 
of the MEFs with chloroquine alone. 
FIG. 5 also demonstrates that treatment with curcumin 
alone enhances Par-4 secretion. The combination of chlo-
roquine and curcumin also improves secretion of Par-4 in 
comparison to treatment with chloroquine or curcumin 
alone. 
The culture media of the treated MEFs secreting elevated 
levels of Par-4 were assayed for their ability to induce 
apoptosis in cancer cells in culture. The assays confirmed 
sufficient Par-4 was secreted to induce enhanced apoptosis 
of cancer cells. 
Materials 
Cells and Plasmids 
Human lung cancer cells A549, H460, H1299, HOP92, 
mouse lung cancer cells LLCl, human prostate cancer cells 
LNCaP, DV145, PC-3, and primary human lung fibroblast 
cells HEL and epithelial cells HBEC and BEAS-2B were 
from ATCC, MD; C4-2B cells were from Leland Chung 
(Ceder Sinai Medical Center, LA), normal human prostate 
stromal cells PrS and prostate epithelial cells PrE were from 
Lonza Inc., Allendale, N.J. KP7B cells were from Tyler 
Jacks, MIT, MA. Par-4+/+ and Par-4_1_ MEFs were derived 
from wild type and Par-4-null C57BL/6 mice (Sato et al., 
2014 J Cell Sci 127:422-431). 
Antibodies and siRNA Duplexes 
Par-4 (R334) for Western blot or ICC; GRP78 (N20), 
CollAl (H-197), VACA, and pan-cytokeratin (Cll) anti-
bodies were from Santa Cruz Biotechnology, Inc. Active 
in inhibiting growth and proliferation (FIG. llA). TheA549 
shPar-4 cells showed reduced radiosensitivity and increased 
growth rate indicating that the action of CQ was dependent 
on Par-4. 
Mel 1617 and Mel 1617BR melanoma cancer cells were 
treated with either vehicle or 1 µM or 5 µM CQ and were 
exposed to O and 4 Gy of radiation respectively (FIG. lOB). 
The Mel 1617 and Mel 1617BR cells showed increased 
radiosensitivity and decreased growth rate, indicating that 
the combination treatment with CQ and ionizing radiation 
has an unexpected greater than additive effect in inhibiting 
growth and proliferation of melanoma cells. 
35 caspase 3 antibody (Aspl 75) (5A1E) and p53 antibody 
(1C12) were from Cell Signaling. The ~-actin antibody was 
from Sigma Chemical Corp. VACA, Rab Sb (ab124356, 
rabbit) and Rab8a (ab 188574, rabbit) antibodies were from 
Abeam (Cambridge, Mass.). Active caspase 3 antibody 
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40 (Asp175) (5A1E) and p53 antibody (1C12) were from Cell 
Signaling. The ~-actin antibody was from Sigma Chemical 
Corp. Rab8b siRNA duplexes were from Dharmacon (D), 
and pools of Rab8b siRNA and scrambled siRNA duplexes 
were from Santacruz Biotechnology (SC). Human GFP 
The results presented herein demonstrate that ibuprofen 
and/or curcumin in combination with chloroquine further 
enhance Par-4 secretion over secretion obtained by any of 
ibuprofen, curcumin, or chloroquine alone. 
45 tagged Rab8B (RG204651), and mouse GFP tagged Rab8b 
(MG202204) were from Origene Technologies, MD. 
MEFs were treated with CQ (25 µM) or vehicle (V) for 24 
h and mRNA prepared from the cells was examined by 
Real-Time quantitative reverse transcription PCR ( qRT-
50 PCR) for Par-4. The data were normalized relative to a 
GAPDH control. (see FIG. SC). To determine whether curcumin or ibuprofen enhanced 
the secretion of Par-4 in cells treated with chloroquine, 
MEFs were treated with chloroquine (25 µM), curcumin (5 
µM and 10 µM) or ibuprofen (500 µM or 750 µM) or 
combinations of chloroquine and curcumin or ibuprofen for 55 
24 hours at 37° C. 
The conditioned medium (CM), as well as the whole-cell 
lysates, were subjected to Western blot analysis with the 
antibodies specific for Par-4, Collagen (CollAl), albumin, 
or actin. CollAl served as a loading control for protein 60 
secretion, as it is generally unchanged in response to the 
treatments. The samples were also subjected to SDS/PAGE 
and Coomassie blue staining to determine albumin levels in 
serum from the CM as another loading control. 
As can be seen in FIG. 5, treatment with ibuprofen alone 65 
does not enhance the production or secretion of Par-4 from 
MEFs. However, surprisingly ibuprofen at 750 µM signifi-
Co-Immunoprecipitation and Western Blot Analysis 
Proteins extracted from cell lysates were resolved by 
SDS-PAGE, and subjected to Western blot analysis as 
described (Yu et al. (2009) "The regulation of the endosomal 
compartment by p53 the tumor suppressor gene". FEES J 
276, 2201-2212. 
Reporter Assays, Apoptosis Assays and Detection 
of Cell Surface GRP78 
To determine the effect of CQ on NF-KB dependent 
transcription, cells were transfected with NF-KB reporter 
construct or minimal-promoter-luciferase vector along with 
~-galactoside construct and then treated with CQ or vehicle. 
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After 24 h, cell lysates were quantified for luciferase activity, 
which was normal relative to the corresponding ~-galacto-
side activity. Apoptotic nuclei were identified by immuno-
cytochemical (ICC) analysis for active caspase-3, and nuclei 
were revealed by 4, 6-diamidino-2-phenylindole (DAPI) 5 
staining (Donehower et al. (1992). "Mice deficient for p53 
are developmentally normal but susceptible to spontaneous 
tumours". Nature 356, 215-221, and; el-Deiry et al. (1992) 
"Definition of a consensus binding site for p53 ". Nat Genet 
1, 45-49). A total of three independent experiments were 10 
performed; and approximately 500 cells were scored in each 
experiment for apoptosis under a fluorescent microscope. 
Cell surface GRP78 expression on the cancer cell surface 
was quantified by FACS analysis in the Flow Cytometry 
15 Shared Resource Facility, Markey Cancer Center as previ-
ously described (Donehower et al. (1992)). 
To determine the effect of CQ on p53-dependent tran-
scription or NF-KB-dependent transcription, MEFs (p53+/+ 
or p53-/-) were transiently co-transfected with p53-re-
20 
sponse element-luciferase reporter PG13-luc (PG13-luc 
containing p53 binding sites) or mutant response element-
luciferase reporter MG15-luc (MG15-luc contammg 
mutated binding sites for p53) (from Addgene), or NF-KB-
luciferase reporter construct, respectively, or with minimal-
25 promoter-luciferase vector pGL3 as control, along with 
~-galactoside construct. The transfectants were treated with 
CQ (25 µM) or vehicle for 24 h, luciferase activity was 
determined and normalized to corresponding ~-galactosi-
dase activity and expressed as relative luciferase activity 
30 
units. After 24 h, cell lysates were quantified for luciferase 
activity, which was normalized relative to the corresponding 
~-galactoside activity, as described (Burikhanov et al., 2009 
Cell 138: 377-388). Cell cycle distribution was accessed 
using propidium iodide staining of wild type or p53-null 
35 MEFs treated with CQ or vehicle in a Becton-Dickinson 
LSRII flow cytometer. CQ induced luciferase activity from 
the p53-reporter luciferase construct but not from a 
luciferase construct containing mutant response element in 
p53+/+ MEFs. By contrast, CQ failed to induce luciferase 
40 
activity in p53-/- MEFs. (see FIG. SA) 
Apoptotic cells were identified by immunocytochemical 
(ICC) analysis for active caspase-3, and apoptotic nuclei 
were revealed by 4, 6-diamidino-2-phenylindole (DAPI) 
staining (Burikhanov et al., 2014b Nature Chem Biol 
45 10:924-926). A total of three independent experiments were 
performed; and approximately 500 cells were scored in each 
experiment for apoptosis under a fluorescent microscope. 
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mouse serum samples were added to the growth medium 
(final 20% mouse serum) of normal and cancer cells in 
culture and tested for induction of ex vivo apoptosis in 
cancer cells. 
To test the effect of CQ on metastatic tumor growth, 
LLCl/luciferase cells (0.5xl06 cells) were injected via the 
tail vein in C57BL/6 mice and 24 h later, the mice were 
injected i.p. with CQ (25 mg/kg body weight) injection 
given daily for five consecutive days. Serum from the mice 
was examined 24 h after the 5th CQ injection for p53, p21, 
PIG3, Par-4, and actin by Western blot analysis (see FIG. 
SB). The mice were imaged for luciferase expression after 
10 days as previously described and humanely killed to 
examine their tumors at day 21, as previously described 
(Zhao et al. Cancer Biol Ther 12:152-157, 2011. PMCID: 
PMC3154287). 
All animal procedures were performed with University of 
Kentucky IACUC approval. Primers used for Real-Time 
quantitative reverse transcription PCR (qRT-PCR) assay 
The primers used were: mRab8a Forward: 5'-CTG-
GCACTCGACTATGGGAT-3' SEQ ID NO: 4; mRab8a 
Reverse: 5'-TTTGCTTTGATATCCCTGGC-3' SEQ ID NO: 
5; mRab8b Forward: 5'-CACGCCTCTTCAGATGTTGA-3' 
SEQ ID NO: 6; mRab8b Reverse: 5'-CGACTTTGCACTT-
GTCTCCA-3' SEQ ID NO: 7; mouse Par-4 Forward: 
5'-AGAATGAAGCTGCGACCCTC-3'; SEQ ID NO: 8 
mouse Par-4 Reverse: 5'-ATCTTCTGGGGC ACTGGTTG-
3' SEQ ID NO: 9; and internal control primers for mGAPDH 
Forward: 5'-GTGAGGCAAAAGGGAAGGTG-3' SEQ ID 
NO: 10; mGAPDH Reverse: 5'-AGGCATGGCAGAT-
TCAG AGT-3' SEQ ID NO: 11. 
Statistical Analysis 
All experiments were performed in triplicate to verify the 
reproducibility of the findings. The results show a mean of 
at least 3 experiments±Standard Deviation (s.d.). Statistical 
analyses were carried out with Statistical Analysis System 
software (SAS Institute, Cary, N.C.) and P values were 
calculated using the Student's t-test. 
The foregoing results demonstrate that CQ induced sig-
nificantly elevated levels of Par-4 systemically in mice and 
in patients following CQ treatment, and these Par-4 levels 
were adequate to induce paracrine apoptosis of diverse 
prostate and lung cancer cells. Importantly, CQ inhibited the 
growth of tumors in a Par-4-dependent manner. Collectively, 
CQ induces paracrine effects via Par-4 secretion from nor-
mal cells leading to tumor cell apoptosis and tumor growth 
inhibition. 
Animal Experiments 
C57BL/6 mice were injected via the intraperitoneal (i.p.) 
route with a single injection of CQ (50 mg/kg body weight) 
or corn oil vehicle, and whole-blood samples were collected 
24 h later. Serum was separated from the blood samples, 
heated at 56° C. to inactivate complement. Aliquots of the 
While certain exemplary embodiments have been 
50 described and shown in the accompanying figures, it is to be 
understood that such embodiments are merely illustrative of 
and not restrictive on the broad invention, and that this 
invention need not be limited to the specific constructions 
and arrangements shown and described, since various other 
modifications may occur to those ordinarily skilled in the art. 
<160> NUMBER OF SEQ ID NOS, 11 
<210> SEQ ID NO 1 
<211> LENGTH, 29 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
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<400> SEQUENCE, 1 
rrrcwwgyyy rrrccccwwg ggggggyyy 
<210> SEQ ID NO 2 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
ggggcacgcc cgaggctccc c 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 3 
ggagagccgc gggcgtgcct 
<210> SEQ ID NO 4 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 4 
ctggcactcg actatgggat 
<210> SEQ ID NO 5 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 5 
tttgctttga tatccctggc 
<210> SEQ ID NO 6 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 6 
cacgcctctt cagatgttga 
<210> SEQ ID NO 7 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 7 
cgactttgca cttgtctcca 
<210> SEQ ID NO 8 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
-continued 
22 
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20 
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20 
20 
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-continued 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 8 
atcttctggg gcactggttg 
<210> SEQ ID NO 9 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 9 
atcttctggg gcactggttg 
<210> SEQ ID NO 10 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 10 
gtgaggcaaa agggaaggtg 
<210> SEQ ID NO 11 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized sequence 
<400> SEQUENCE, 11 
aggcatggca gattcagagt 
20 
20 
20 
20 
I claim: 
1. A method of treating a p53-deficient human lung or 
prostate cancer cell that is nonresponsive to chloroquine, or 
salt or prodrug thereof, said method comprising contacting 
7. The method of claim 1, wherein the method further 
comprises administering an effective amount of ionizing 
40 radiation to the cancer cell. 
a population of human lung or prostate cancer cells com-
prising the p53-deficient human lung or prostate cancer cell 
that is nonresponsive to chloroquine, or salt or prodrug 
thereof, and normal cells that are responsive to chloroquine, 45 
or salt or prodrug thereof, with about 100 nM to about 25 µM 
of chloroquine, or salt or prodrug thereof, wherein such 
treatment induces Par-4 production by the normal cells that 
are responsive to chloroquine, wherein the p53-deficient 
human lung or prostate cancer cell is killed, cancer cell 50 proliferation is inhibited, cancer cell metastasis is inhibited, 
and/or recurrence of one or more tumors comprising the 
p53-deficient human lung or prostate cancer cell is inhibited. 
2. The method of claim 1, wherein the chloroquine or salt 
or prodrug thereof is chloroquine phosphate, chloroquine 
diphosphate, or hydroxychloroquine. 55 
3. The method of claim 1, wherein the p53-deficient 
human lung or prostate cancer cell is a p53-deficient human 
prostate cancer cell. 
4. The method of claim 1, wherein the p53-deficient 
human lung or prostate cancer cell is a p53-deficient human 60 
lung cancer cell. 
5. The method of claim 1, wherein the method further 
comprises contacting the normal cells with an effective 
amount curcumin. 
6. The method of claim 1, wherein the method further 65 
comprises contacting the normal cells with an effective 
amount of ibuprofen. 
8. The method of claim 1, wherein the chloroquine is not 
co-administered with a chemotherapeutic. 
9. A method of inhibiting p53-deficient human lung or 
prostate cancer cell proliferation, lung or prostate cancer cell 
metastasis, and/or recurrence of lung or prostate tumors in a 
subject comprising administering about 100 nM to about 25 
µM of chloroquine phosphate, chloroquine diphosphate, 
hydroxychloroquine, or salt or prodrug thereof to a subject 
in need thereof, wherein the chloroquine phosphate, chlo-
roquine diphosphate, hydroxychloroquine, or salt or prodrug 
thereof is not co-administered with a chemotherapeutic, and 
wherein prostate apoptosis responsive 4 (Par-4) secretion 
from normal cells in the subject is increased. 
10. The method of claim 9, wherein the p53-deficient 
human lung or prostate cancer cell is a p53-deficient human 
prostate cancer cell. 
11. The method claim 9, wherein the lung or prostate 
cancer cell is a p53-deficient human lung cancer cell. 
12. The method of claim 9, wherein the chloroquine 
phosphate, chloroquine diphosphate, hydroxychloroquine, 
or the salt or the prodrug thereof is administered in a divided 
dose twice daily. 
13. The method of claim 9, wherein the method further 
comprises administering ionizing radiation to the cancer 
cell, wherein the chloroquine phosphate, chloroquine 
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diphosphate, hydroxychloroquine, or salt or prodrug thereof 
sensitizes the cancer cell to the ionizing radiation. 
* * * * * 
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